MX2012002139A - Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer. - Google Patents

Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer.

Info

Publication number
MX2012002139A
MX2012002139A MX2012002139A MX2012002139A MX2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A
Authority
MX
Mexico
Prior art keywords
antibody
cmet
diagnosis
prognosis
disorders associated
Prior art date
Application number
MX2012002139A
Other languages
English (en)
Inventor
Liliane Goetsch
Alexandra Jouhanneaud
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2012002139A publication Critical patent/MX2012002139A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con el campo del pronóstico y/o diagnosis de una enfermedad proliferativa en un paciente. Más específicamente, la invención se relaciona con un novedoso anticuerpo con capacidad para unirse específicamente al receptor cMet humano, como así también las secuencias de aminoácidos y ácidos nucleicos que codifican este anticuerpo. La invención comprende asimismo el uso de dicho anticuerpo y los correspondientes procesos para la detección y diagnóstico de trastornos patológicos oncogénicos hiperproliferativos asociados a la expresión de cMet. En ciertas realizaciones, los trastornos son trastornos oncogénicos asociados a la expresión incrementada del polipéptido cMet con respecto a lo normal o cualquier otra patología asociada a la sobreexpresión de cMet. La invención comprende, por último, productos y/o composiciones o kits que comprenden por lo menos dicho anticuerpo para el pronóstico o diagnóstico de ciertos cánceres.
MX2012002139A 2009-08-21 2010-08-23 Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer. MX2012002139A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23586409P 2009-08-21 2009-08-21
EP09305777A EP2287197A1 (en) 2009-08-21 2009-08-21 Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US34800510P 2010-05-25 2010-05-25
PCT/EP2010/062271 WO2011020925A1 (en) 2009-08-21 2010-08-23 Anti-cmet antibody and its use for the detection and the diagnosis of cancer

Publications (1)

Publication Number Publication Date
MX2012002139A true MX2012002139A (es) 2012-03-07

Family

ID=41571045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002139A MX2012002139A (es) 2009-08-21 2010-08-23 Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer.

Country Status (19)

Country Link
US (2) US8673302B2 (es)
EP (2) EP2287197A1 (es)
JP (1) JP5951486B2 (es)
KR (1) KR20120051734A (es)
CN (1) CN102639564B (es)
AR (1) AR077901A1 (es)
AU (1) AU2010284944B2 (es)
BR (1) BR112012003759A2 (es)
CA (1) CA2769427C (es)
ES (1) ES2692522T3 (es)
IL (1) IL218202A (es)
IN (1) IN2012DN01322A (es)
MX (1) MX2012002139A (es)
NZ (2) NZ598194A (es)
RU (1) RU2582265C2 (es)
SG (1) SG178339A1 (es)
TW (1) TW201111781A (es)
WO (1) WO2011020925A1 (es)
ZA (1) ZA201202076B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US20120089541A1 (en) 2010-08-31 2012-04-12 Genentech, Inc. Biomarkers and methods of treatment
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
WO2013043715A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
CN104395752B (zh) * 2011-11-21 2017-09-15 泰纬生命科技股份有限公司 对hec1活性调节剂具有反应的癌症的生物标记
RU2014124842A (ru) 2011-11-21 2015-12-27 Дженентек, Инк. Очистка анти-с-мет антител
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
EP2870178B1 (en) * 2012-05-09 2017-07-12 Eli Lilly and Company Anti-c-met antibodies
US10377827B2 (en) * 2012-06-21 2019-08-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
WO2015031626A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015032695A1 (en) * 2013-09-09 2015-03-12 Ventana Medical Systems, Inc. Scoring method for mesothelin protein expression
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
US10544210B2 (en) * 2015-02-03 2020-01-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Rho GTPase conformational single domain antibodies and uses thereof
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
MX2017011432A (es) * 2015-03-18 2017-11-10 Seattle Genetics Inc Anticuerpos contra cumulo de diferenciacion 48 (cd48) y sus conjugados.
CN108601834B (zh) 2016-02-05 2022-05-03 赫利世弥斯株式会社 抗间质-上皮细胞转化因子抗体及其用途
SI3626273T1 (sl) 2016-05-17 2021-04-30 Abbvie Biotherapeutics Inc. Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
RU2735918C2 (ru) * 2018-06-07 2020-11-10 Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" Набор реагентов для выявления маркера эпителиальных карцином
JP7332194B2 (ja) * 2018-06-29 2023-08-23 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｐｄ－ｌ１結合ポリペプチドおよびそれらの使用
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
JP2022535880A (ja) * 2019-06-06 2022-08-10 アポロミクス インコーポレイテッド（ハンジョウ） ｃ－ＭＥＴ阻害剤を使用して癌患者を処置するための方法
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN115297889A (zh) 2020-09-01 2022-11-04 荣昌生物制药(烟台)股份有限公司 抗c-Met抗体药物偶联物及其应用
IL300952A (en) * 2020-09-08 2023-04-01 Ideaya Biosciences Inc Drug combination and tumor treatment
WO2024030341A1 (en) 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
JP2005527488A (ja) * 2001-12-27 2005-09-15 バン アンデル リサーチ インスティチュート Ｍｅｔを発現し、肝細胞増殖因子と結合する腫瘍のモノクローナル抗体画像化および治療
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
WO2007056523A2 (en) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
AU2007213804B2 (en) * 2006-02-06 2012-12-13 Vertical Bio Ag Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer

Also Published As

Publication number Publication date
AR077901A1 (es) 2011-09-28
EP2467402B1 (en) 2018-08-01
NZ700437A (en) 2016-04-29
BR112012003759A2 (pt) 2017-07-11
WO2011020925A1 (en) 2011-02-24
CA2769427C (en) 2020-03-10
ZA201202076B (en) 2012-11-28
EP2467402A1 (en) 2012-06-27
AU2010284944A1 (en) 2012-03-08
IN2012DN01322A (es) 2015-06-05
AU2010284944B2 (en) 2016-01-28
CN102639564B (zh) 2015-01-07
EP2287197A1 (en) 2011-02-23
US8673302B2 (en) 2014-03-18
RU2012109004A (ru) 2013-09-27
ES2692522T3 (es) 2018-12-04
KR20120051734A (ko) 2012-05-22
JP5951486B2 (ja) 2016-07-13
RU2582265C2 (ru) 2016-04-20
SG178339A1 (en) 2012-03-29
IL218202A (en) 2017-07-31
US20140295452A1 (en) 2014-10-02
CA2769427A1 (en) 2011-02-24
NZ598194A (en) 2015-05-29
TW201111781A (en) 2011-04-01
JP2013502213A (ja) 2013-01-24
IL218202A0 (en) 2012-04-30
CN102639564A (zh) 2012-08-15
US20120149031A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
MX2012002139A (es) Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer.
MX2012014739A (es) Novedoso anticuerpo para el diagnostico y/o pronostico de cancer.
ATE551073T1 (de) Markierte hgf-bindende peptide für bildgebung
GB0718967D0 (en) Peptide imaging agents
WO2011028698A3 (en) Mri and optical assays for proteases
MX2010000405A (es) Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos.
EP2502628A3 (en) Polynucleotides and polypeptide sequences involved in cancer
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
WO2009120905A3 (en) Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2010027903A8 (en) Lung cancer diagnosis
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
WO2007120311A3 (en) Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
WO2010045495A3 (en) Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
NZ599707A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
WO2009007958A3 (en) Compositions, methods and kits for the diagnosis of carriers of mutations in the brca1 and brca2 genes and early diagnosis of cancerous disorders associated with mutations in brca1 and brca2 genes
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
NZ605640A (en) Signal biomarkers
WO2011141153A8 (en) Methods for the diagnosis and prognosis of a tumor using bcat1 protein
MX2014008306A (es) Medios y metodos para tratar o diagnosticar canceres positivos a idh1 r132h mutante.
WO2009052255A3 (en) Novel therapeutic targets in bowel disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal